Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track SCTX with free AI briefings, catalyst countdowns, and dilution alerts.

SCTX · Scribe Therapeutics Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$174.2M Cash on Hand
46.4mo Cash Runway
Follow SCTX by email Get an email when SCTX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about SCTX, unsubscribe in one click. Privacy

📣 What SCTX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
STX-1150 Elevated LDL-C and High Cholesterol Phase 1 · NCT07428473 Recruiting

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

SCTX holds $174.2M in cash and short-term investments (as of Sep 30, 2026) and burns about $11.3M/quarter from operations, an estimated runway of 46.4 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when SCTX files for a raise →

👥 Who Owns SCTX

Insiders 54.1% Institutions (43 holders) 45.9% Public and other holders 0%
HolderTypeShares% of sharesAs of
Behzad Aghazadeh
Director, 10% owner · +14,725 options
Insider 3,088,888 16.31% 2026-07-24
AH Bio Fund II, L.P.
10% owner
Insider 3,082,725 16.28% 2026-07-27
RA Capital Management, L.P. Institution (13G, 5%+) 1,802,178 9.52% 2026-07-27
ORBIMED ADVISORS LLC
Director
Insider 1,348,825 7.12% 2026-07-27
Carl L Gordon
Director · +14,725 options
Includes shares also reported by ORBIMED ADVISORS LLC, counted once
Insider 1,348,825 7.12% 2026-07-23
LILLY & Co ELI
10% owner
Insider 1,054,828 5.57% 2026-07-23
Jennifer A Doudna
10% owner
Insider 603,547 3.19% 2026-07-27
Brett Staahl
10% owner · +43,525 options
Insider 524,336 2.77% 2026-07-23
Benjamin L. Oakes
President, CEO, Director · +707,352 options
Insider 506,602 2.68% 2026-07-23
Svetlana Lucas
Chief Business Officer · +228,399 options
Insider 30,695 0.16% 2026-07-23
David Parrot
Chief Financial Officer · +227,761 options
Insider 2,666 0.01% 2026-03-13

Share count 18,937,519 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full SCTX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SCTX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.